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Abstract
Genomic copy number aberrations and corresponding transcriptional deregulation in the cancer
genome have been suggested to have regulatory roles in cancer development and progression.
However, functional evaluation of individual genes from lengthy lists of candidate genes from
genomic datasets presents a significant challenge. Here we report effective gene selection strategies
to identify potential driver genes based on systematic integration of genome scale data of DNA copy
numbers and gene expression profiles. Using regional pattern recognition approaches, we discovered
the most probable copy number-dependent regions and 50 potential driver genes. At each step of
gene selection process, functional relevance of the selected genes was evaluated by estimating the
prognostic significance of the selected genes. Further validation using small interference RNA
(siRNA)-mediated knockdown experiments demonstrated proof-of-principle evidence for the
potential driver roles of the genes in HCC progression (i.e., NCSTN and SCRIB). In addition, systemic
prediction of drug responses implicated the association of the 50 genes with specific signaling
molecules (mTOR, AMPK, and EGFR). In conclusion, the application of an unbiased and integrative
analysis of multidimensional genomic datasets can effectively screen for potential driver genes and
provides novel mechanistic and clinical insights into pathobiology of HCC.
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Introduction
Microarray technologies have been used to define the global gene expression patterns in human
cancer and have successfully identified gene expression signatures or novel tumor classes as
well as prognostic information (1–4). However, since the gene expression profile is only a
snapshot of complex genetic interactions, it is difficult to discriminate the genes driving the
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neoplastic process (“driver” genes) from by-stander genes (“passenger” genes). Array-based
comparative genomic hybridization (CGH) analyses have also identified DNA copy number
changes in many cancers. Some of these copy number-altered loci have been linked to disease
pathogenesis and clinical behavior (5–8), but many of the copy number-altered genes appear
not to be expressed. Thus, it seems reasonable to suggest that the combined analysis of both
datasets may reveal the causally altered genes in both copy numbers and corresponding gene
expression (9–12). However, dauntingly complex genomic and epigenomic interactions in
cancer and the current limitations in sensitivity and specificity of genomic data may impede
the identification of the regulatory genes (13). It is therefore challenging to evaluate the
biological function and clinical utility of the lengthy candidate genes obtained from genomic
data.
In this study, we aimed to establish a gene selection strategy to identify potential driver genes
by integrating genomic data of copy numbers and gene expression profiles. Guiding our gene
selection process by estimating the prognostic significance of the selected genes, we identified
50 potential driver genes. Further computational and experimental interrogations suggested
that the identified genes represent potential driver genes for HCC providing both new insights
into the pathobiology of liver cancer and therapeutic opportunities.
Materials and Methods
CGH Profiling
Genomic DNA of 15 HCC samples and a normal reference liver were extracted using DNeasy
extraction kit (Qiagen, Valencia, CA). After labeling tumors and a reference normal liver DNA
samples with Cy5 and Cy3 fluorescent dye, respectively, hybridizations and data acquisition
were performed following the manufacturer’s instructions (Nimblegen, Madison, WI). The
raw data were normalized as described previously (14).
Generation of TM and TCM
The regional copy number alteration was estimated by T-statistic–based sliding window
approach, T-statistic map (TM). Before constructing TM, considering the absolute copy
number values exceeding 0.5 in at least three samples to be significant, 309,939 out of
3,080,000 probes were identified as having non-trivial changes. TM scores were calculated as
the T-statistic values which were obtained by applying one-sample T-test on the probe values
for 15 samples within a moving window. We chose 100 Kb as the best-fit window size as it
most accurately reflects the genomic copy number changes when various different window
sizes (100 Kb, 1 Mb, and 10 Mb) were tested (data not shown). The TM scores generated by
less than 5 probes in a moving window were regarded as missing values. The threshold for
significant TM score was determined as the highest TM score from 100 random datasets which
were generated by randomly ordering the probe positions. Significant TM regions were
determined by a segmentation algorithm. The probes above the threshold were determined as
valid probes. If a valid probe was not neighbored within 100 Kb of another valid probe, it was
regarded invalid. Then, if the valid probes were neighbored over 5 Mb, the probe position
between them was segmented. Segments less than 100 Kb were excluded.
Regional concordance of transcriptional regulation in 139 HCC expression profiles were
constructed using transcriptome correlation map (TCM) as described previously (13). Briefly,
for each gene, the sum of pair-wise Pearson’s correlation coefficients of the gene expression
levels in neighboring n genes was calculated. Moving window size was determined to include
the largest significant genes with the smallest neighboring genes, n=24. The threshold for
significant TCM values and the segments were determined by the same algorithms used in the
TM analysis.
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Estimation of the Prognostic Values of Gene Sets
The prognostic value (P0) of a selected gene set was evaluated by using a clustering algorithm
and log-rank test as described previously (4). Then, a permutation test was performed to
compare the prognostic value of a selected region with those from other regions. 2,000 random
datasets were generated by randomly selecting the same number of genes from outside the
selected regions (or genes) to be tested. For each random dataset, hierarchical clustering was
performed to stratify the HCCs into two groups, and the log-rank test P-value (Pm) between
the groups was calculated. Iterative hierarchical clustering for the 2,000 random datasets was
performed by a command-line version of Cluster 3.0 (15). The significance of the permutation
test was taken as the frequency of events Pm < P0 from the 2,000 trials. Prognostic impact
score (PIS) was calculated as − log10 (permutation P-value). A permutation P < 0.05 (PIS >
1.3) was regarded as significant.
siRNA-mediated Gene Knockdown
HepG2 and HuH-7 cells were transfected with siGENOME SMARTpool siRNAs
(Dharmacon, Lafayette, CO) for the selected target genes using lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Non-targeting siRNA
(siGENOME Non-Targeting Pool #1 siRNA) was used as control. After 96 hrs incubation with
siRNAs, the cell viability was assessed by MTT assay.
Screening of Therapeutic Drugs using in trans correlated gene signatures
Raw data of Connectivity Map (build01) with two different Affymetrix platforms (i.e., hgu133a
and HT-hgu133a) were downloaded from authors’ website (www.broad.mit.edu/cmap/) and
normalized independently using the RMA method implemented in Bioconductor
(http://www.bioconductor.org). For each of the in trans gene signatures, positive or negative
signatures were assigned according to the algebraic sign of the correlation coefficient of each
gene. For each treatment instance, the average connectivity score for the in trans gene
signatures was calculated as the representative connectivity score (Savg). The connectivity
scores (Si) for each in trans gene signature to drug treatment instance (i) were calculated based
on Kolmogorov-Smirnov test and the significance of the connectivity of a perturbagen was
evaluated by a permutation test for 10,000 times as described previously (16).
Additional procedures are described in Supplementary Materials and Methods.
Results
Comparison of Gene Copy Number and Transcription Levels in HCC
We generated fine-scale whole genome copy number profiles of 15 HCC samples using CGH
microarrays containing 3,080,000 isothermal oligonucleotide probes. To represent the HCC
heterogeneity, we selected 5 tumor samples from each of the subgroups of A, B, and HB which
were previously defined as having homogeneous expression patterns with prognostic
differences [Supplementary Table S1] (1, 4). First, we screened for the copy number altered
regions in HCC by applying the T-statistic map (TM) method. TM was optimized to identify
chromosomal regions with low stringent but high regional concordance of copy number
changes, which yielded 57 TM regions. These regions were highly concordant with previous
findings including the recurrent gains at 1q, 3q, 6p, 7q, 8q, 17q, 20q, 22q and the losses at 1p,
6q, 8p, 9p, 14q, 16q, and 17p (Fig. 1A and SI Table 2A)(7, 10, 13, 17, 18).
To assess the chromosomal regional influence of the gene expression, we next rearranged the
previous 139 HCC gene expression data (4) according to a sequence map of the human genome
(hg17), which revealed a strong regional concordance of gene expression patterns across the
heterogeneous tumor samples (Fig. 1B). This regional pattern can be shown more clearly with
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a transcriptome correlation map (TCM). TCM was previously used to identify concordant
regional coexpression which was thought to be largely due to the copy number alteration (Fig.
1C)(19). With a TCM, we identified 48 regions in which gene expression levels were likely to
be copy number-dependent (Supplementary Table S2B). Remarkably high TCM scores were
observed in chromosome 8, implying strong influence of the copy numbers on gene expression
levels. This agrees well with the previous studies indicating marked copy number aberration
of chromosome 8 and its regulatory role in cancer development and progression (20,21). We
then cross-compared the TM and TCM regions, which yielded 25 overlapped common regions
(CR) spanning 112.8 Mb and containing 580 genes (Supplementary Table S2C). These regions
may represent the most plausible regions in which copy numbers and expressions are
concomitantly deregulated.
Prognostic Impact of the Copy Number-Dependent Regions
We hypothesized that if genomic alterations of the genes in CR are critical events during HCC
development, the gene expression patterns in CR would be well associated with patient
prognosis. We evaluated the prognostic relevance of the selected regions by calculating
prognostic impact score (PIS) which may represent the relative prognostic significance
compared to the non-selected regions. The TM and TCM regions showed significant log-rank
test P-values, but their PIS were not significant compared to the other regions (Fig. 2A).
However, the genes residing in the common regions (CR) showed a significant prognostic
value (PIS=1.62), which may suggest that the genes in CR play regulatory roles in the HCC
progression (Fig. 2A). In particular, 4 out of the 25 CR segments (CR1:1q21.3-23.2, CR3:
1q42.11-42.12, CR13: 7q36.1, and CR20: 8q24.11-24.22) were highly predictive for patient
survival (P<0.001, Fig. 2B). CR13 was significant in predicting tumor recurrence as well as
survival (Fig. 2C). Deregulated genes in these regions (1q21, 1q42, 7q36, and 8q24) may
therefore have a high probability of functioning as potential driver genes.
Screening of the Potential Driver Genes
Next, we tested whether the previous correlation-based gene selection method (9,11) can
identify the potential driver genes which have prognostic relevance. Before gene selection, we
evaluated the genome-wide influence of all copy number changes on gene expression. The
distribution correlation coefficients showed significant global influence of the copy number
changes on the gene expression levels (Supplementary Fig. S1A). Moreover, the copy number
profile of each sample was best correlated with its corresponding expression levels,
demonstrating that the overall copy number changes substantially reflected the gene expression
profiles in each individual genome (Supplementary Fig. S1B).
Confident that the copy number changes were strongly reflected in the corresponding gene
expression levels, we selected 379 correlated copy number alteration (corCNA) genes based
on the correlation between the expression levels and the copy numbers (P<0.01, r>0.649,
Pearson’s correlation test, false discovery rate=0.0019). To validate the correlation by an
independent method, we measured the copy numbers of two corCNA genes (POLR2K and
C1orf43) in 52 HCC samples using qPCR (Supplementary Fig. S1C,D). However, the
prognostic impact of the 379 genes was not significantly different from the non-correlated
genes (PIS=0.76) even though the log-rank test revealed a significant difference (Fig. 3A,
top). We next selected the corCNA genes residing in CR, which yielded 50 genes. Strikingly,
these 50 corCNA genes showed a strong prognostic impact (P=5.06 × 10−6, PIS=2.03, Fig.
3A, middle). This result suggests that our gene selection strategy using the regional pattern
recognition approach can effectively select the functionally relevant genes. Thus, we reasoned
that these 50 genes were the most probable candidate driver genes (Table 1).
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Interestingly, of the 50 corCNA genes, 30 genes resided in 1q (n=8) and 8q (n=22) which were
previously shown to have copy number gains at the early stage of HCC development (7). The
prevalence of 1q and 8q genes among 50 corCNA genes is unlikely to be due to the gene
abundance in those regions (P=9.42 × 10−5, hypergeometric test). These 30 genes in the “early
event” regions (1q21.3-42.12 and 8q21.13-24.13) showed the most significant prognostic
relevance (P=1.32 × 10−7; PIS=3.30; Fig. 3A, bottom), indicating the importance of the early
dysregulation of these genes in HCC development. The prognostic values of the 50 or 30 1q/
8q corCNA genes were further validated by two independent HCC datasets (SNU (22) and
GSE6764 (2)) using class prediction algorithms (for details see SI Methods). The tumor classes
defined by the expression similarity of the 50 or 30 genes could successfully predict the
prognostic outcome of HCC in the independent datasets (Supplementary Fig. S2 & Table S3),
supporting the robustness and consistency of our finding.
The enrichment of the 1q and 8q genes among the 50 corCNA genes raised the possibility that
the gene expression alterations at 1q and 8q might concomitantly occur during the early stage
of HCC development. We observed that the average copy numbers of 1q and 8q corCNA genes
were correlated to each other (r=0.564, P=0.028; Fig. 3B). In parallel, the gene expression
levels of 1q and 8q corCNA genes were also correlated in our 139 HCC dataset (r=0.333,
P=6.17 × 10−5, permutation P=0.042; Fig. 3C), and this was validated in an independent 35
HCC dataset (GSE6764, r=0.398, P=0.017; Fig. 3D). In addition, the result from GSE6764
also showed that the coexpression levels of the 1q and 8q genes corresponded with the
pathological staging of the liver (cirrhosis, dysplasia, and early HCC), and advanced HCC
(n=65, r=0.609, P=7.11 × 10−8, permutation P=0.005; Fig. 3D). Permutation tests from 10,000
random trials indicated that our findings are not likely to be observed by chance. Taken
together, the 30 corCNA genes might be co-amplified and coexpressed during the early stage
and play critical roles in HCC development and progression.
Functional Assessment and Identification of Therapeutic Targets for the 50 Genes
Since the 50 genes were selected by unbiased screening, we next examined their potential driver
roles. We randomly chose 11 genes from the 50 genes to include the copy number-gained genes
in the distinct chromosomes (CCT3, SCRIB, PYCR2, HSF1, NCSTN, EPHB4, MTDH,
CCNE1, RRM2B, TATDN1, and POLR2K) and tested the siRNA-mediated knockdown effects
on the cancer cell viability. Of the 11 genes, 5 siRNAs for SCRIB, NCSTN, HSF1, TATDN1,
and POLR2K significantly reduced the viability of both HepG2 and HuH-7 liver cancer cell
lines (P < 0.01, Fig. 4A). In particular, the loss of NCSTN and SCRIB showed the most potent
growth inhibition (P < 0.001) supporting the potential driver role of these genes in HCC
development and making them attractive therapeutic targets. The knockdown of each 5
effective target genes was confirmed by qRT-PCR, and its target selectivity was validated by
two independent siRNAs (Supplementary Fig. S3). These results show that our screening
strategy can successfully identify novel therapeutic targets for HCC. The 50 potential driver
genes were identified by computational and experimental methods. However, the global
influence of the 50 genes on cell function might be mediated by their target effector genes. We
therefore sought to identify the putative effector genes whose expression levels were correlated
in trans with expression of each driver gene (P<0.001, Pearson’s correlation test). Overall, the
in trans correlated gene sets (ranged from 15 to 1,606) were enriched with the cancer-dominant
functions such as protein transport/translation, oxidative stress, RNA processing/DNA
replication, and metabolism/immune related functions; this may support their representative
roles for the effector genes (Supplementary Fig. S4). Considering the in trans correlated genes
as putative effectors for the 50 genes, we hypothesized that the disruption of the expression of
the in trans correlated genes would interrupt HCC development. To test this hypothesis, we
employed Connectivity Map, an analytical resource of gene expression profiles for drug
responses (16). For each of the 50 in trans gene signatures, we calculated the connectivities to
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the drug instances in the Connectivity Map. The connectivity score profiles of the 50 in
trans gene sets showed overall similar connectivities against each treatment instance,
suggesting the commonality of their connectivities to the drug responses (Fig. 4B). Therefore,
we used the averaged connectivity score of the 50 in trans gene sets (Savg) as a representing
connectivity to each treatment instance. We found only two perturbagens, metformin and
sirolimus (rapamycin), to be significantly connected to the Savg (permutation P=0.0025 and
0.0082, respectively; Fig. 4B). In addition, gefitinib, an EGFR selective tyrosine kinase
inhibitor, was also identified as having significant connectivity (Savg=−0.335 and ranked to
7th out of 453 instances). Since only one instance for gefitinib was available in Connectivity
Map (build01), we performed permutation test by treating all the EGFR/IR selective tyrosine
kinase inhibitors as a same perturbagen (n=7). This revealed a strong connectivity of the EGFR
tyrosine kinase inhibitors to Savg (permutation P=0.0022; Fig. 4B). These results may suggest
that the dysregulated potential driver genes can be interrupted by rapamycin, metformin, or
gefitinib treatment.
Interestingly, the cross-talk among the target molecules of rapamycin, metformin, and gefitinib
has been reported (i.e., mTOR, AMPK, and EGFR )(23). This supports the idea that a
combination of these drugs may provide clinical benefit for HCC patients (24). We found that
the combined treatment with these drugs could potentiate the growth inhibition of cancer cells
as compared to the expected potency calculated by Bliss independence model (for review see
(25)) (Fig. 4C).
In addition, our data suggest a novel link between the 50 genes and the EGFR, AMPK, and
mTOR signaling pathways. To verify this notion, we examined the knockdown effects of
NCSTN and SCRIB on the mTOR signaling which is thought to be a common target for the
three signaling pathways. Western blot analysis demonstrated that the knockdown of
NCSTN and SCRIB could indeed inhibit the phosphorylation of p70S6 kinase, one of mTOR
targets (Fig. 4D).
Discussion
In this study, we conducted combined analysis of copy numbers and gene expression with the
following unbiased strategies. By applying regional pattern recognition approach, TM and
TCM, we could identify the most probable copy number-dependent genes. In each step of our
gene selection strategy, the functional relevance of the selected genes was evaluated by
estimating the prognostic impact from the expression patterns and clinical information.
Although our study was not intended to classify prognostic groups using the copy numbers or
the gene expression patterns, we adopted clustering algorithm and log-rank test to calculate
PIS which allowed evaluation of the functional relevance of our gene selection strategy. Our
analysis revealed 50 potential driver genes which have significant prognostic relevance.
Indeed, the 50 genes included many cancer related genes. For example, RRM2B, HAX1,
CUTL1, HSF1, EPHB4, and MTDH were known to regulate tumorigenesis, tumor migration
or adhesion. The genes related to RNA processing/transcription (e.g., ADAR, ELP3,
HMBOX1, POLR2K, ZHX1, and KARS) and cell cycle regulation (e.g., BRD4, CCNC, and
CCNE1) were also identified.
The functional significance of the 50 genes was further evaluated in part by siRNA-mediated
knockdown experiments. Particularly, NCSTN, encoding a gamma-secretase component,
showed the most potent effect on cancer cell growth in our screening. Supporting our finding,
NCSTN was previously identified as one of the copy number-dependent genes in HCC (11).
Moreover, inhibition of gamma-secretase has been reported to reduce leukemia cell growth
via Notch and mTOR signaling pathways (26). SCRIB was also known to associate with human
cancers (27), but its oncogenic role is not yet fully understood. Loss of HSF1 inhibited cancer
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cell growth (Fig. 4) in an agreement with the recent identification of HSF1 as an oncogene
(28). Taken together, our data successfully demonstrate the potential driver roles of the 50
genes, and suggest that our strategy can efficiently identify novel therapeutic targets.
The application of the in trans correlated genes to mine the Connectivity Map allowed us to
identify the therapeutic targets for the 50 genes. In the past, the Connectivity Map has been
used to predict the therapeutic targets or diseases from gene expression signatures (16,29,30).
Differing from these studies, we utilized in trans correlated gene signatures to predict the
molecular targets which were functionally associated with each of the 50 genes. In support of
our approach, the coexpressed genes in microarray data have been previously shown to be
functionally related (31). Accordingly, our in silico approach could predict relevant effector
targets without generating experimental signatures for each of the driver genes. Identification
of common connectivities (Savg) from 50 different signatures might be also helpful in reducing
by-chance findings which can be generated by applying a single signature. Indeed, our
approach was able not only to predict well-known anticancer drugs with recognized therapeutic
potential for HCC, such as rapamycin and gefitinib (8,32–36), but also identified metformin
as a therapeutic drug for targeting the 50 in trans gene signatures. Metformin is a widely used
hypoglycemic drug for diabetes patients. Recently, several studies have shown its anticancer
effect, suggesting a novel utility of the anti-metabolic drugs for cancer treatment (15,37,38).
Supporting these studies, we observed for the first time the therapeutic efficacy of metformin
for HCC using single or combination regimens for treating HCC cell lines in vitro (Fig. 4C).
Our analysis also predicted novel links between the 50 genes and mTOR, AMPK, and EGFR
pathways. Supporting this notion, the oncogenic function of HSF1 has been reported to be
mediated by mTOR (22) and EGFR (39) pathways. Likewise, we demonstrated that the
knockdown effects of NCSTN and SCRIB are possibly mediated through these pathways.
Although further stringent validations for the mechanism(s) might be required, our findings
open new opportunities for studying the multifaceted association of the 50 genes with the three
identified pathways.
In conclusion, we suggest that our unbiased gene selection strategy of integrating
multidimensional genomic data can effectively select the potential driver genes and provide
new biological and clinical insights into the copy number-dependent genes in HCC.
Undoubtedly, our strategy can be applied to other cancer types.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the staff of Laboratory Experimental Carcinogenesis for critical reading of the manuscript. This project was
supported by the Intramural Research Program of the Center for Cancer Research/NCI, and, in part, by FG-4-2 of the
21C Frontier Functional Human Genome Project from the Ministry of Science & Technology in Korea.
References
1. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by
gene expression profiling. Hepatology 2004;40:667–76. [PubMed: 15349906]
2. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia
and hepatocellular carcinoma. Hepatology 2007;45:938–47. [PubMed: 17393520]
3. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular
carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416–
23. [PubMed: 12640447]
Woo et al. Page 7













4. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma
derived from hepatic progenitor cells. Nat Med 2006;12:410–6. [PubMed: 16532004]
5. Paris PL, Andaya A, Fridlyand J, et al. Whole genome scanning identifies genotypes associated with
recurrence and metastasis in prostate tumors. Hum Mol Genet 2004;13:1303–13. [PubMed: 15138198]
6. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-
pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313–25. [PubMed:
16616336]
7. Poon TC, Wong N, Lai PB, Rattray M, Johnson PJ, Sung JJ. A tumor progression model for
hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology 2006;131:1262–
70. [PubMed: 17030195]
8. Katoh H, Ojima H, Kokubu A, et al. Genetically distinct and clinically relevant classification of
hepatocellular carcinoma: putative therapeutic targets. Gastroenterology 2007;133:1475–86.
[PubMed: 17983802]
9. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy
number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A
2002;99:12963–8. [PubMed: 12297621]
10. Patil MA, Chua MS, Pan KH, et al. An integrated data analysis approach to characterize genes highly
expressed in hepatocellular carcinoma. Oncogene 2005;24:3737–47. [PubMed: 15735714]
11. Lee SA, Ho C, Roy R, et al. Integration of genomic analysis and in vivo transfection to identify sprouty
2 as a candidate tumor suppressor in liver cancer. Hepatology 2008;47:1200–10. [PubMed:
18214995]
12. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of
hepatocellular carcinoma. Cancer Res 2008;68:6779–88. [PubMed: 18701503]
13. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription
in cancer. Nat Genet 2006;38:1386–96. [PubMed: 17099711]
14. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics
2004;20:1453–4. [PubMed: 14871861]
15. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic Treatment with the Antidiabetic Drug Metformin
Selectively Impairs p53-Deficient Tumor Cell Growth. Cancer Res 2007;67:6745–52. [PubMed:
17638885]
16. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to
connect small molecules, genes, and disease. Science 2006;313:1929–35. [PubMed: 17008526]
17. Su WH, Chao CC, Yeh SH, et al. HCC: an integrated oncogenomic database of hepatocellular
carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 2007;35:D727–31.
[PubMed: 17098932]
18. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat
Genet 2002;31:339–46. [PubMed: 12149612]
19. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P. Chromosome alterations in human
hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative
CGH meta-analysis. Br J Cancer 2005;92:935–41. [PubMed: 15756261]
20. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-
scale transcriptional signatures in cancer. Nat Genet 2006;38:421–30. [PubMed: 16518402]
21. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect
risk for prostate cancer. Nat Genet 2007;39:638–44. [PubMed: 17401364]
22. Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-
related human hepatocellular carcinoma. Clin Cancer Res 2008;14:2056–64. [PubMed: 18381945]
23. Guertin DA, Sabatini DM. Defining the Role of mTOR in Cancer. Cancer Cell 2007;12:9–22.
[PubMed: 17613433]
24. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with
EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer
2008;98:923–30. [PubMed: 18319715]
25. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the
quest for clinical efficacy. Nat Chem Biol 2006;2:458–66. [PubMed: 16921358]
Woo et al. Page 8













26. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the
mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278–86. [PubMed:
17363738]
27. Kamei Y, Kito K, Takeuchi T, et al. Human scribble accumulates in colorectal neoplasia in association
with an altered distribution of beta-catenin. Hum Pathol 2007;38:1273–81. [PubMed: 17509663]
28. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier
of carcinogenesis. Cell 2007;130:1005–18. [PubMed: 17889646]
29. Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic
prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006;10:321–30.
[PubMed: 17010675]
30. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin
as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331–42. [PubMed:
17010674]
31. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P. Coexpression analysis of human genes across many
microarray data sets. Genome Res 2004;14:1085–94. [PubMed: 15173114]
32. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression
in primary liver neoplasms. Clin Cancer Res 2004;10:8421–5. [PubMed: 15623621]
33. Parent R, Kolippakkam D, Booth G, Beretta L. Mammalian target of rapamycin activation impairs
hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular
growth. Cancer Res 2007;67:4337–45. [PubMed: 17483347]
34. Villanueva A, Chiang DY, Newell P, et al. Pivotal Role of mTOR Signaling in Hepatocellular
Carcinoma. Gastroenterology 2008;135:1972–1983. [PubMed: 18929564]
35. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with
advanced hepatocellular cancer. J Clin Oncol 2005;23:6657–63. [PubMed: 16170173]
36. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable
hepatocellular carcinoma. Cancer 2007;110:1059–67. [PubMed: 17623837]
37. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269–73. [PubMed: 17062558]
38. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect
in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576–86. [PubMed:
18212742]
39. O’Callaghan-Sunol C, Sherman MY. Heat shock transcription factor (HSF1) plays a critical role in
cell migration via maintaining MAP kinase signaling. Cell Cycle 2006;5:1431–7. [PubMed:
16855393]
Woo et al. Page 9














Identification of genomic regional patterns of DNA copy numbers and mRNA expression in
HCC. A, T-statistic map (TM ) was constructed based on one-sample T-statistic values of the
copy numbers in 15 HCCs with moving window size 100 Kb. B, Gene expression profiles of
139 HCC samples in the order of chromosomal location. C, Transcriptome correlation map
(TCM) for the gene expression profiles of 139 HCC. Thresholds for TM (29.9) and TCM (28.7)
were determined by 100 random permutation tests.
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Prognostic impacts of T-statistic map (TM) or transcriptome correlation map (TCM) regions.
A, Kaplan-Meir plot analyses (left) and prognostic impact scores (PIS)(right) of the genes
located in the TM, TCM, and CR regions are shown, respectively. To show the significance
of the PIS, the distribution of log-rank test P-values generated from 2,000 random datasets
(Pm) were plotted with the log-rank test P-values calculated from the selected gene sets (P0,
red line). B, Kaplan-Meir plot analyses and log-rank tests for overall survival and recurrence
free survival (C) in the HCC subgroups based on expression similarities of the genes located
in the CR1, CR3, CR13, and CR20.
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Correlation of gene copy numbers and transcriptional levels. A, Kaplan-Meir plot analyses
(left) and prognostic impact scores (PIS) (right) of 379 (top), 50 (middle), and 30 (bottom)
Correlated copy number alteration (corCNA) genes are shown, respectively. B, scatter plot for
the average copy numbers of the corCNA genes at 1q vs. 8q in 15 HCC dataset. C-D, Scatter
plots for the average gene expression levels of corCNA genes at 1q vs. 8q in 139 HCC (C) and
GSE6764 dataset (D). Pathological phenotypes of cirrhotic liver (n = 13, black), dysplastic
nodules (n = 17, blue), early HCC (n = 18, pink), and advanced HCC (n = 17, red) are indicated
with different colors in D. The significance of the correlation coefficients was evaluated by
10,000 random permutation test (P = 0.042, P = 0.005, respectively).
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Evaluation of functional and clinical utility of the 50 in trans correlated genes. A, The siRNAs
(15 nM) targeting 11 driver genes were transfected to HepG2 and HuH-7 cells for 96 hrs, and
the cell viabilities were assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. Non-targeting control siRNA(NT-CTL) was used as a
control. Each bar indicates mean percentage cell viability of three replicates compared to NT-
CTL. Error bars represent mean ± SD. Significance of growth inhibition compared to NT-CTL
for each cell line was evaluated by two-sample T-test (* P <0.05, ** P < 0.01, and *** P <
0.001). B, Connectivity scores for each of the in trans correlated gene signatures to
Connectivity Map are shown in a heatmap ordered by the average connectivity scores for
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individual instances (Savg). Bar-views with the instances of metformin (M, n = 5), rapamycin
(R, n = 10), and EGFR/IR selective tyrosine kinase inhibitors (i.e., gefitinib, 4,5-
dianilinophthalimide, butein, tyrophostin AG-1478, and HNMPA-(AM)3) (G, n = 7). Ranked
distribution of Savg for the interesting perturbagen is indicated as a black line in the ordered
453 instances. Other instances with positive and negative connectivity scores are indicated
with green and red color, respectively. C, HuH-7 cells were treated with rapamycin (R, 10 nM),
metformin (M, 1 mM), or gefitinib (G, 1 μM) for 48 hrs in serum free media, and the cell
viability was assessed by MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay. The % cell viability of three replicates compared to the control group (red bar)
and the expected viability of combination treatment (blue bar) are indicated. Error bars indicate
mean ± SD. Significance of the growth inhibition effects compared to the control or expected
value E were evaluated by two-sample T-test (*P<0.05, **P<0.01, and ***P<0.001). D, HuH-7
cells were transfected with siRNAs (15 nM) targeting NCSTN or SCRIB for 48 hrs, and Western
blot analysis was performed using antibodies for p70 S6 kinase (p70S6K), phospho-p70 S6
kinase (pp70S6K), and β-actin.
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